Rocket Pharmaceuticals Inc sell geldnutzer
Start price
21.11.24
/
60%
€12.44
Target price
21.11.25
€1.00
Performance (%)
-79.72%
End price
22.11.25
€2.52
Summary
This prediction ended on 22.11.25 with a price of €2.52. geldnutzer correctly predicted massive losses of -79.72% for Rocket Pharmaceuticals Inc. geldnutzer has 60% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Rocket Pharmaceuticals Inc | -0.523% | -0.523% | 35.591% |
| iShares Core DAX® | 0.734% | 1.458% | 17.980% |
| iShares Nasdaq 100 | -2.686% | -0.146% | 3.810% |
| iShares Nikkei 225® | -2.261% | -2.729% | 11.679% |
| iShares S&P 500 | -1.346% | 0.467% | 1.970% |
According to geldnutzer what are the pros and cons of Rocket Pharmaceuticals Inc for the foreseeable future?
Pros
Revenue growth >5% per year expected
Valuable balance sheet
Good culture
Top 10 in its market
Could be worthwhile Investment >10% per year
Growths faster than the competition
Stable Large shareholder and/or long term investor
EBIT growth >5% per year expected
positive Cash Flow expected
Standard Investments for future growth
Normal challenges to pay loans and raise capital
Capable Management
Innovative
Sustainability is important
Medium risks for its business
Future proof or reliable business model
Cons
Few uniques
Dependend from some customers or products
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected
Significant cyclical dependencies
Little known brand
ROE lower than 10% per year
Comments by geldnutzer for this prediction
In the thread Rocket Pharmaceuticals Inc diskutieren
Sell mit Kursziel 15,0
Kursziel geändert auf 5,0
Kursziel geändert auf 3,0
Kursziel geändert auf 1,0
In the thread Trading Rocket Pharmaceuticals Inc
Die von geldnutzer gewählte maximale Laufzeit wurde überschritten
Stopped prediction by geldnutzer for Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€18.02
16.09.24
16.09.24
€21.00
16.09.25
16.09.25
-30.95%
21.11.24
21.11.24
Revenue growth >5% per year expected
Valuable balance sheet
Good culture
Few uniques


